Zdrowie i gospodarka · 16/06/2014

FDA Requests Public Comments on Method for Evaluating Cancer as Adverse Outcome of Non-Oncology Drugs and Biologicals

The US Food and Drug Administration (FDA) is hosting a public meeting to discuss methodological considerations for evaluating cancer as an adverse outcome associated with the use of non-ontological drugs and biological products in the post-approval setting, and is seeking public comments on the topic